PTPN11 and myasthenia gravis: Indeed, similar to what was observed with pharmacological inhibition of SHP-2, the inhibition of SHP-2 function using knockdown strategies partially reversed MG-induced monocyte dysfunction as seen by the efficient responses (18 ± 11.7%) towards arteriogenic stimuli, PlGF-1 (Fig. 3h).